Abstract
Background Previous studies showed that remnant cholesterol(RC) partially explained the residual risk of cardiovascular disease. We tried to test the hypothesis that remnant cholesterol is a risk factor for all-cause mortality in oldest-old(>80 years old) patients with acute coronary syndrome(ACS).
Methods 662 oldest-old patients with acute coronary syndrome and undergoing coronary angiography were finally included in our study. Remnant cholesterol(RC) was calculated by fasting total cholesterol(TC) minus low-density lipoprotein cholesterol(LDL-C) and high-density lipoprotein cholesterol(HDL-C). Multivariable Cox regression analysis was used to identify the association between RC and all-cause mortality. Receiver operating characteristic(ROC) curve was used to compare the discrimination capacity of RC, TC, HDL-C and LDL-C to predict all-cause mortality.
Results Among the 662 oldest-old patients enrolled, 92.90% accepted statin therapy. The average age was 81.87 ± 2.14 years old. In the fully-adjusted Cox regression model, the Hazard ratio(HR) [95% confidence interval (CI)] of all-cause mortality was 1.17 (1.01, 1.36) for each standard deviation(SD) increase in RC. Compared to tertile 1, tertile 3 was associated with a 130% increased risk of all-cause mortality (HR:2.30;95%CI:1.45, 3.63). The increased risk of death from tertile 1 to tertile 3 was statistically significant (P for trend<0.001). The subgroup analysis confirmed the significant association between RC and all-cause mortality. ROC curve showed that RC had a better discrimination capacity at predicting all-cause mortality and improved the prognostic value of the Gensini score combined with left ventricular ejection fraction(LVEF).
Conclusion Remnant cholesterol was associated with all-cause mortality in oldest-old patients with ACS in a long-term follow-up.
What is already known
(1) Remnant cholesterol was a risk factor for atherosclerotic cardiovascular disease(ASCVD);
(2) Emerging studies reported that RC was associated with all-cause mortality in general population, patients with disease status including ischemic heart disease(IHD), heart failure(HF) and metabolic dysfunction-associated fatty liver disease(MAFLD) or patients receiving special treatment such as peritoneal dialysis(PD) and kidney transplantation;
(3) However, some studies found that there was no correlation between RC and all-cause mortality.
What this study adds
(1) We focused on oldest-old ACS patients who underwent angiography and found that RC was associated with all-cause mortality in this special population;
(2) The correlation between RC and all-cause mortality was dose–response;
(3) RC had a better discrimination capacity at predicting all-cause mortality and improved the prognostic value of the Gensini score combined with LVEF.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was performed in accordance with the Declaration of Helsinki and approved by the medical ethics committee of the Chinese PLA General Hospital. All participants provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
